Overview: HyQvia is an injection given under your skin for certain immune system problems or inflammatory conditions. Common side effects can include pain, itching, swelling, or redness near where you ...
HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase], the Only up to Once Monthly (every 2, 3 or 4 weeks) Subcutaneous Immunoglobulin (SCIG) Infusion to Treat CIDP, Can ...
After a gradual adjustment period, the Hyqvia dose is 300-600 mg/kg, every 3 to 4 weeks. The dose is adjusted individually based on body weight, medical history, symptom severity, and treatment ...
HyHub and HyHub Duo Reduce the Number of Steps Required to Prepare HYQVIA 1 First Devices Customized for a Plasma-Derived Therapy in Takeda’s Broad and Differentiated Portfolio Reflect Company’s ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced full results from the pivotal Phase 3 ADVANCE-CIDP 1 clinical trial investigating HYQVIA® [Immune Globulin ...
OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Takeda (TSE:4502/NYSE:TAK) today announced data from the Phase 3 ADVANCE-CIDP 3 clinical trial, a long-term extension study evaluating the safety and ...
DEERFIELD, Ill. & SAN DIEGO--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the United States Food and Drug Administration ...
DEERFIELD, Ill. & SAN DIEGO--(BUSINESS WIRE)--Baxter International Inc. (NYSE:BAX) and Halozyme Therapeutics, Inc., (NASDAQ:HALO) today announced that the Blood Products Advisory Committee (BPAC) of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results